Martin has over 30 years experience in research and scientific commercialisation, including early research positions in the HHMI laboratories at the Yale University School of Medicine in the US and the MRC Laboratory of Molecular Biology in Cambridge, UK.
After 15 years in academic research he moved to the commercial sector to work on the development of biopharmaceuticals and most recently he was an IP and commercialisation specialist for Plant Bioscience Ltd.
He was Founder and CSO of a biotech company developing engineered antibody fragments (Iclectus Ltd.) and has also managed a specialist CRO (The Model Gut), which he successfully sold to a Danish-based CRO, Bioneer A/S.
Martin is a Director of antibiotic developer Procarta Biosystems Limited and has raised close to £17m in VC and translational funding for early-stage ventures/projects.
He has negotiated and secured over 50 service or licensing deals including with major pharma (Merck & Co., Novartis, GSK, Pfizer), animal health (Elanco, Ceva), and agbio (Monsanto, Syngenta) companies as well as mid-tier entities and SMEs, active in both the food and pharma sectors.
